Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 97

Results For "disease"

3230 News Found

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China
Clinical Trials | November 30, 2025

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders


Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
Clinical Trials | November 28, 2025

Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients

The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio


Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies
R&D | November 28, 2025

Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies

GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030


Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech
News | November 27, 2025

Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech

The fresh capital will propel Cordance into its first-in-human clinical trial


Glenmark launches world’s first nebulized triple therapy for COPD
News | November 27, 2025

Glenmark launches world’s first nebulized triple therapy for COPD

Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness


Dr. Lal PathLabs launches India's first complement testing lab
News | November 27, 2025

Dr. Lal PathLabs launches India's first complement testing lab

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards


EU greenlights Dupixent for chronic urticaria, offering new hope to patients
Drug Approval | November 27, 2025

EU greenlights Dupixent for chronic urticaria, offering new hope to patients

It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria